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Oral food challenges still remain the gold standard in
the diagnosis of food related symptoms and are per-
formed to obtain a clear “yes or no” response. However,
this is often difficult to achieve, and so proposals may
be appropriate for criteria on when to stop oral food
challenges and declare a challenge as positive or nega-
tive. In daily practice it makes sense to challenge until
clear objective symptoms occur without harming the
patient. Clinical symptoms should be objective and/or:
(a) severe or (b) reproducible or (c) persisting. A sensi-
tive parameter for a beginning clinical reaction is a gen-
eral change of mood. The sooner symptoms appear, the
more likely they are to represent a “true” positive reac-
tion, and the more organ systems are involved the easier
it is to assess an oral food challenge as positive. In the
case of subjective symptoms, the number of placebo
doses should be increased. In unclear situations, the
observation time until the next dose should be pro-
longed or the same dose repeated. Transient objective
clinical symptoms usually end up in a positive challenge
result. There are a number of causes for false positive
and false negative challenge results, which should be
considered. The aim of all oral challenge testing should
be to hold the balance between two conflicting aspects:
on the one hand the need to achieve clear and justified
results from oral food challenges in order to avoid
unnecessary diets, and on the other hand to protect
patients from any harm caused by high doses of a
potentially dangerous food.
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